TY - JOUR
T1 - Addressing the need for patient-friendly medical communications
T2 - adaptation of the 2019 recommendations for the management of MPS VI and MPS IVA
AU - Bruce, Iain A.
AU - Ezgü, Fatih S.
AU - Kampmann, Christoph
AU - Kenis, Vladimir
AU - Mackenzie, William
AU - Stevens, Bob
AU - Walker, Robert
AU - Hendriksz, Christian
N1 - Funding Information:
The authors would like to thank Terri Klein, President and Chief Executive Officer of the National MPS Society, Durham, North Carolina, United States of America, for her input during the initial stages of manuscript development, and the PAG UK MPS Society for their consultation on the design of the infographics. Medical writing and editorial support for the authors during the preparation of this manuscript was provided by William Jones, MBiochem, of Adelphi Communications Ltd., Adelphi Mill, Macclesfield, East Cheshire, United Kingdom. Financial support for these services was provided by BioMarin Pharmaceutical Inc.
Funding Information:
This manuscript was funded by BioMarin. BioMarin was not involved in any stage of content development for this manuscript and did not influence the design or content in any way. BioMarin was not included in any correspondence between the authors regarding this manuscript.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: Patients are the most important stakeholders in the care of any disease and have an educational need to learn about their condition and the treatment they should receive. Considering this need for patient-focused materials, we present a directed approach for mucopolysaccharidosis (MPS) VI and MPS IVA, a pair of rare, inherited diseases that affects multiple organs and parts of the body. Independent guidelines on the treatment of these diseases were recently published, providing evidence- and expertise-driven recommendations to optimize patient management. However, while healthcare providers may have the training and knowledge to understand these guidelines, patients and their caregivers can find the technical content challenging. Hence, we aimed to develop plain language summaries (PLS) of the MPS VI and MPS IVA guidelines with patients as the primary audience. Results: A review of the guidelines by an expert team identified six domains of information relevant to patients: The multidisciplinary team, regular tests and check-ups, disease-modifying and supportive treatments, general anesthetics, ear-nose-throat/respiratory care, and surgeries. This information was adapted into a series of infographics specific to either MPS VI or MPS IVA, designed to appeal to patients and clearly present information in a concise manner. Conclusions: The use of patient-friendly materials, like the infographics we have developed, has the potential to better inform patients and engage them in their care. We issue a “call to arms” to the medical community for the development of similar PLS materials in rare diseases intended to inform and empower patients.
AB - Background: Patients are the most important stakeholders in the care of any disease and have an educational need to learn about their condition and the treatment they should receive. Considering this need for patient-focused materials, we present a directed approach for mucopolysaccharidosis (MPS) VI and MPS IVA, a pair of rare, inherited diseases that affects multiple organs and parts of the body. Independent guidelines on the treatment of these diseases were recently published, providing evidence- and expertise-driven recommendations to optimize patient management. However, while healthcare providers may have the training and knowledge to understand these guidelines, patients and their caregivers can find the technical content challenging. Hence, we aimed to develop plain language summaries (PLS) of the MPS VI and MPS IVA guidelines with patients as the primary audience. Results: A review of the guidelines by an expert team identified six domains of information relevant to patients: The multidisciplinary team, regular tests and check-ups, disease-modifying and supportive treatments, general anesthetics, ear-nose-throat/respiratory care, and surgeries. This information was adapted into a series of infographics specific to either MPS VI or MPS IVA, designed to appeal to patients and clearly present information in a concise manner. Conclusions: The use of patient-friendly materials, like the infographics we have developed, has the potential to better inform patients and engage them in their care. We issue a “call to arms” to the medical community for the development of similar PLS materials in rare diseases intended to inform and empower patients.
KW - Anesthetics
KW - Enzyme replacement therapy
KW - Management guidelines
KW - MPS IVA
KW - MPS VI
KW - Mucopolysaccharidosis
KW - Patient education
KW - Patient engagement
KW - Rare diseases
KW - Surgery
UR - https://www.scopus.com/pages/publications/85125597129
U2 - 10.1186/s13023-022-02219-7
DO - 10.1186/s13023-022-02219-7
M3 - Article
C2 - 35236367
AN - SCOPUS:85125597129
SN - 1750-1172
VL - 17
JO - Orphanet Journal of Rare Diseases
JF - Orphanet Journal of Rare Diseases
IS - 1
M1 - 91
ER -